Tags

Type your tag names separated by a space and hit enter

Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease.
Aliment Pharmacol Ther. 2017 06; 45(11):1403-1412.AP

Abstract

BACKGROUND

Non-alcoholic fatty liver disease (NAFLD) is known to be associated with polycystic ovary syndrome (PCOS). However, most studies investigated the prevalence of NAFLD in obese PCOS patients.

AIM

To compare the prevalence of non-obese NAFLD in women with or without PCOS, and to assess an independent association between PCOS and NAFLD in a non-obese Asian cohort.

METHODS

This was a case-control study using a prospective PCOS cohort. After subjects with other potential causes of chronic liver disease were excluded, 275 non-obese women with PCOS and 892 non-obese controls were enrolled. NAFLD was determined by hepatic ultrasonography. Main outcomes were the prevalence of NAFLD on hepatic ultrasonography between non-obese women with or without PCOS, and an independent association between non-obese NAFLD and PCOS.

RESULTS

Non-obese women with PCOS had a significantly higher prevalence of NAFLD than those without PCOS (5.5% vs. 2.8%, P = 0.027). PCOS was associated with non-obese NAFLD (odds ratio: 2.62, 95% confidence intervals: 1.25-5.48) after adjustment for age and body mass index (BMI). In women with PCOS, the level of androgenicity represented by free testosterone or free androgen index was associated with NAFLD after adjustment for age, BMI, lipid profile, insulin resistance or glycaemic status.

CONCLUSIONS

Non-obese NAFLD is more prevalent in women with polycystic ovary syndrome than in those without. In non-obese patients with polycystic ovary syndrome, hyperandrogenemia may be an independent risk factor for non-obese NAFLD.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, Healthcare System Gangnam Center, Seoul National University Hospital, Seoul, Korea. The Institute of Reproductive Medicine and Population, Medical Research Center, Seoul National University College of Medicine, Seoul, Korea.Department of Internal Medicine, Healthcare System Gangnam Center, Seoul National University Hospital, Seoul, Korea. Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.Department of Internal Medicine, Healthcare System Gangnam Center, Seoul National University Hospital, Seoul, Korea.Department of Radiology, Healthcare System Gangnam Center, Seoul National University Hospital, Seoul, Korea.Department of Obstetrics and Gynecology, Healthcare System Gangnam Center, Seoul National University Hospital, Seoul, Korea.Department of Obstetrics and Gynecology, Healthcare System Gangnam Center, Seoul National University Hospital, Seoul, Korea.Department of Obstetrics and Gynecology, Seoul Municipal Boramae Hospital, Seoul, Korea.The Institute of Reproductive Medicine and Population, Medical Research Center, Seoul National University College of Medicine, Seoul, Korea. Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.The Institute of Reproductive Medicine and Population, Medical Research Center, Seoul National University College of Medicine, Seoul, Korea. Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.The Institute of Reproductive Medicine and Population, Medical Research Center, Seoul National University College of Medicine, Seoul, Korea. Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.The Institute of Reproductive Medicine and Population, Medical Research Center, Seoul National University College of Medicine, Seoul, Korea. Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28370150

Citation

Kim, J J., et al. "Polycystic Ovary Syndrome With Hyperandrogenism as a Risk Factor for Non-obese Non-alcoholic Fatty Liver Disease." Alimentary Pharmacology & Therapeutics, vol. 45, no. 11, 2017, pp. 1403-1412.
Kim JJ, Kim D, Yim JY, et al. Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2017;45(11):1403-1412.
Kim, J. J., Kim, D., Yim, J. Y., Kang, J. H., Han, K. H., Kim, S. M., Hwang, K. R., Ku, S. Y., Suh, C. S., Kim, S. H., & Choi, Y. M. (2017). Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics, 45(11), 1403-1412. https://doi.org/10.1111/apt.14058
Kim JJ, et al. Polycystic Ovary Syndrome With Hyperandrogenism as a Risk Factor for Non-obese Non-alcoholic Fatty Liver Disease. Aliment Pharmacol Ther. 2017;45(11):1403-1412. PubMed PMID: 28370150.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease. AU - Kim,J J, AU - Kim,D, AU - Yim,J Y, AU - Kang,J H, AU - Han,K H, AU - Kim,S M, AU - Hwang,K R, AU - Ku,S Y, AU - Suh,C S, AU - Kim,S H, AU - Choi,Y M, Y1 - 2017/03/30/ PY - 2016/12/02/received PY - 2016/12/13/revised PY - 2017/03/02/revised PY - 2017/03/04/accepted PY - 2017/4/4/pubmed PY - 2017/9/5/medline PY - 2017/4/4/entrez SP - 1403 EP - 1412 JF - Alimentary pharmacology & therapeutics JO - Aliment Pharmacol Ther VL - 45 IS - 11 N2 - BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is known to be associated with polycystic ovary syndrome (PCOS). However, most studies investigated the prevalence of NAFLD in obese PCOS patients. AIM: To compare the prevalence of non-obese NAFLD in women with or without PCOS, and to assess an independent association between PCOS and NAFLD in a non-obese Asian cohort. METHODS: This was a case-control study using a prospective PCOS cohort. After subjects with other potential causes of chronic liver disease were excluded, 275 non-obese women with PCOS and 892 non-obese controls were enrolled. NAFLD was determined by hepatic ultrasonography. Main outcomes were the prevalence of NAFLD on hepatic ultrasonography between non-obese women with or without PCOS, and an independent association between non-obese NAFLD and PCOS. RESULTS: Non-obese women with PCOS had a significantly higher prevalence of NAFLD than those without PCOS (5.5% vs. 2.8%, P = 0.027). PCOS was associated with non-obese NAFLD (odds ratio: 2.62, 95% confidence intervals: 1.25-5.48) after adjustment for age and body mass index (BMI). In women with PCOS, the level of androgenicity represented by free testosterone or free androgen index was associated with NAFLD after adjustment for age, BMI, lipid profile, insulin resistance or glycaemic status. CONCLUSIONS: Non-obese NAFLD is more prevalent in women with polycystic ovary syndrome than in those without. In non-obese patients with polycystic ovary syndrome, hyperandrogenemia may be an independent risk factor for non-obese NAFLD. SN - 1365-2036 UR - https://www.unboundmedicine.com/medline/citation/28370150/Polycystic_ovary_syndrome_with_hyperandrogenism_as_a_risk_factor_for_non_obese_non_alcoholic_fatty_liver_disease_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=28370150.ui DB - PRIME DP - Unbound Medicine ER -